St. Jude Children's Research Center

Memphis, TN

Sorting 2 by

Accepting patients

LANTERN

Larotrectinib to Enhance RAI Avidity in Patients With Differentiated Thyroid Cancer Harboring NTRK Fusions
Learn more
  • Tyrosine Kinase (TK) Inhibitor
  • Radiation
  • Phase 2

Accepting patients

CARE Study

A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations
Learn more
  • Tyrosine Kinase (TK) Inhibitor
  • Phase 1/2
  • Has results